NYSE · Healthcare · Forecast & analysis
Abbott Laboratories (ABT) Stock Forecast & Analyst Ratings
Median target, high/low range, buy/hold/sell mix, conviction spread, and bull/base/bear scenarios from the latest analyst data.
Section freshness
Prices as of Sep 4, 4:04 PM EDT · Fundamentals checked Sep 8, 7:46 AM EDT · Statements Mar 31, 2026
Forecast read
ABT target implies +10.96% from current.
Use this dashboard to see whether Wall Street expects ABT to grow, stall, or drop before you dive into the raw financial data.
Price target map
Today to 12 months out
Data last updated: Sep 4, 2026, 4:04 PM EDT
Consensus target
$120.20
+10.96% from current
Consensus
Buy
33 analysts tracked
Rating score
4.12
Analyst consensus score on 1-5 scale
Dispersion
0.77
Moderate Consensus Divergence
- High target
- $135.00
- +24.62% bull case
- Low target
- $103.00
- -4.92% bear case
- Analyst disagreement
- +29.54%
- High target minus low target, divided by current price
TECHi take
ABT consensus has a target, but the rating mix still matters.
TECHi Markets Desk · Sep 4, 2026, 4:04 PM EDT
TECHi is tracking 33 analyst ratings on Abbott Laboratories, with consensus at Buy and a rating score of 4.12. Dispersion tells you whether that consensus is broad or clustered.
The primary target is $120.20, implying +10.96% from the latest quoted price. TECHi still separates the base target from the bull and bear range because the spread is what tells investors whether analysts agree or are simply clustering around a headline number.
Use the sections below to compare the rating split, estimate revisions, and peer forecasts. When target data is available, the scenario view expands into explicit bull, base, and bear cases with the high and low targets shown below.
TECHi Signal
ABT scores 52/100: Balanced watch.
The Signal model blends ABT's price tape, valuation, analyst inputs, and risk into a single 52/100 read with low confidence on 67/76 inputs. Its nearest horizon stance is Hold. The factor evidence, horizon matrix, and price-direction backtest live on the Signal page so this forecast stays focused on analyst targets and scenarios.
Open the ABT Signal pageAnalyst consensus
What the street actually thinks right now.
ABT currently has 33 analyst entries with a live Wall Street consensus score of 4.12 (Buy).
Dispersion score: 0.77 · Moderate Consensus Divergence.
Adjusted score for spread: 3.69 · used to reduce false certainty when recommendations are split.
Consensus read: Lopsided bullish
Signal-vs-consensus divergence
ABT current TECHi Signal stance against analyst consensus.
Consensus: 4.12 (Buy) · Signal: 3.08 (Balanced watch) · gap -1.04 on the 1-5 scale
Dispersion reliability: usable. If consensus is split, a small gap is still meaningful, while a wide gap usually means framing differences.
TECHi Signal is more cautious than consensus.
TECHi Signal can diverge from consensus on 3M+ horizons because it blends financial data, governance signals, leadership quality, and quant scores (Altman Z, ROIC, Rule of 40, FCF yield) alongside standard analyst inputs.
- Consensus
- Buy
- Rating score
- 4.12
- 1 sell to 5 strong buy scale
- Adjusted score
- 3.69
- Disciplined by disagreement
- Buy weight
- 76%
- 25 buy / strong buy
- Hold + Sell pressure
- 24%
- 8 hold + sell
Current distribution of recommendations in TECHi’s analyst dataset.
Analyst strength
Buy and strong-buy split
Buy minus sell
Analyst indecision proxy
Forward estimates
What analysts are modeling for the next year.
- Revenue estimate
- $50.30B
- Range $50.06B to $50.78B
- Revenue analysts
- 26
- Contributors in estimate data
- EPS estimate
- 5.52
- Range 5.48 to 5.57
- EPS analysts
- 25
- Contributors in estimate data
- EPS revisions 30d
- 5 up / 1 down
- Trailing 30-day estimate changes
Forecast math
The real risk and reward behind the numbers.
These numbers answer one retail-investor question: if you buy today, how much reward or risk are analysts putting on the table?
Moves vs current price
Primary target vs live price
Highest target vs live price
Lowest target vs live price
Spread & asymmetry
Gap between the highest and lowest targets
Bull upside divided by bear downside
Bull target above the base target
Bear target below the base target
Scenario framing
What the ABT target range actually means for each scenario.
Bull case
$135.00
+24.62% from current
Highest active analyst target. Represents the most optimistic execution scenario currently modeled by sell-side desks.
In plain English: the best-case number on the table today if everything goes perfectly.
Base case
$120.20
+10.96% from current
Consensus 12-month target from the latest sell-side data. Median target $120.00.
In plain English: this is the single number most analysts are clustering around right now.
Bear case
$103.00
-4.92% from current
Lowest active target. Captures the bear-case execution risk in current models — not necessarily a price the market expects to print.
In plain English: the worst-case number analysts are still publishing, even if they don’t expect it to happen.
Frequently asked
Common questions.
Is ABT a buy?
Analysts currently rate Abbott Laboratories (ABT) "Buy" across 33 tracked ratings (25 buy, 8 hold, and 0 sell). The primary 12-month target is $120.20 (+10.96% from the latest quote). This is the reported Wall Street consensus, not personalized investment advice — review the full rating mix, dispersion, and bull/base/bear scenarios below before deciding.
What is the price target for ABT?
Analysts' primary 12-month price target for ABT is $120.20 (+10.96% from the latest quote).
What is the analyst consensus on ABT?
ABT's current analyst consensus is Buy across 33 tracked ratings.
What is ABT's 12-month forecast?
Analysts' 12-month price targets for ABT run from $103.00 at the low end to $135.00 at the high end, with a primary target of $120.20 (+10.96% from the latest quote).
What analysis is available for ABT?
The ABT Forecast page brings together the analyst rating mix, 12-month target range, bull, base, and bear scenarios, catalysts, and risk context for Abbott Laboratories.
Does TECHi publish its own ABT research?
Related TECHi analyst notes appear when a reviewed report is connected to ABT; consensus-provider data remains separately identified.